UNSPSC 51172820: Cetylpyridinium chloride/chlorophyl copper complex

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR500. This VA Drug Class (OR500) classifies this compound as belonging to the group MOUTHWASHES.

UNSPSC 51172820 Cetylpyridinium chloride/chlorophyl copper complex is a Commodity code that captures pharmaceutical and over-the-counter product manufacturing and supply, as evidenced by state and local procurement activity focused on establishing contracts for generic multi-source drugs and OTC products to supply government health facilities across multiple jurisdictions. State and local government buyers under this code include cooperative purchasing alliances administering agreements on behalf of participating state agencies and municipalities seeking to standardize pharmaceutical procurement across their networks. The work involves manufacturers supplying products through authorized pharmaceutical wholesalers, certifying compliance with Good Manufacturing Practices and the Drug Supply Chain Security Act, maintaining specified insurance coverage, and accepting pricing structures negotiated through competitive proposal processes.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued the most recent opportunity—a Request for Proposal (S1070000015802) posted January 20, 2026, with proposals due March 26, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products supplying participating state and local government facilities in Minnesota and Oregon. The RFP evaluates vendors on price competitiveness (75 percent weight), fixed pricing, administrative compliance, EDI capability, and acceptance of a 3 percent administrative fee, with awarded vendors effective July 1, 2026, and a two-year contract term for new responders. Vendors must maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen/Cencara, Cardinal Health, Morris & Dickson) and demonstrate pricing flexibility through flat price, net price, or WAC-minus structures. No specific set-aside restrictions are identified in the solicitation.